Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 141 participants.
Also called NCT05450328
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 141 participants
- Sponsor
- Registry
-
NCT05450328
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT05450328. Randomized; triple masking; primary purpose treatment. Start 2025-12-10 (actual); primary completion 2028-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation
- Acronym
- MILAN
- Condition
- Right Heart Failure
- Condition
- Right Ventricular Dysfunction
- Intervention (Drug)
- Combined Epoprostenol Sodium & Milrinone
- Intervention (Drug)
- Normal saline
- Lead sponsor
- Montreal Heart Institute
Record details
- Record id
cardio:ct-nct05450328- Content hash
d47499d1fbb5cce307090b115ca2cef5729e3aa6af0e160e38f0efc9694bb5f2